Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obexelimab in Warm Autoimmune Hemolytic Anemia (SApHiAre)
NCT05786573Phase 3Active, not recruiting
- Sponsor
- Zenas BioPharma
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of obexelimab in warm autoimmune hemolytic anemia (wAIHA), sponsored by Zenas BioPharma. Started Sep 2023; status: active, not recruiting.
02
Drugs
obexelimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT05786573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786573.